Takeda Pharmaceutical Company Limited announced the United States commercial availability of LIVTENCITY? (maribavir), the first and only treatment for adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet. LIVTENCITY, an orally bioavailable anti-CMV compound, became available for prescription on December 2, 2021, just over a week after the U.S. Food and Drug Administration (FDA) approval which took place on November 23, 2021. LIVTENCITY is now available to healthcare providers through a network of specialty pharmacies and distributors. LIVTENCITY is a new molecular entity which targets CMV at UL97, resulting in inhibition of viral DNA replication, encapsidation, and nuclear egress. Though a rare disease overall, CMV is one of the most common infections experienced by transplant recipients, with an estimated incidence rate of around 16%?56% in solid organ transplant (SOT) recipients and 30%?70% in hematopoietic stem cell (HSCT) transplant recipients. CMV can be acquired or reactivated following transplant leading to serious consequences?including loss of the transplanted organ and failure of the graft?or loss of life. In patients with compromised immunity, CMV causes clinically challenging complications that can be fatal.